Concepedia

Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects

Zhuang Miao, Gianluca Nucci, Neeta B. Amin, Raman Sharma, Vincent Mascitti, Meera Tugnait, Alfin D. N. Vaz, Ernesto Callegari, Amit S. Kalgutkar

Drug Metabolism and Disposition · 2012 · 119 citations · 24 references

DOI

Concepts

References

24

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

Ralph A. DeFronzo · Diabetes · 2009 · 3K citations · Full text

, , +17

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Clifford J. Bailey, Jorge Luiz Gross, Anne Pieters et al. · The Lancet · 2010 · 857 citations

, , +13

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Y. Kanai, W S Lee, Dennis Brown et al. · Journal of Clinical Investigation · 1994 · 624 citations · Full text

, , +15

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 603 citations

, , +17

The sodium/glucose cotransport family SLC5

Ernest M. Wright, Eric Turk · Pflügers Archiv - European Journal of Physiology · 2004 · 534 citations · Full text

, , +6